Oncology

Market-Access Considerations for Biosimilars in Oncology

May 29th 2020

Determining Biosimilars' Role in the Formulary

May 29th 2020

Switching to Available Biosimilars in Oncology

May 29th 2020

Biosimilars: Addressing Roadblocks to Market Adoption

May 29th 2020

Are Biosimilar Costs a Factor for Patients?

May 29th 2020

Biosimilars in Oncology: Equivalency and Cost

May 29th 2020

Current State of Biosimilars: Approval, Availability, and Efficacy

May 29th 2020

Biosimilars in Oncology: Addressing Awareness

May 29th 2020

Biosimilar Pegfilgrasim Cuts OCM Expense, ASCO Study Finds

May 29th 2020

By Tony Hagen

A study presented at ASCO20 Virtual demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.

Fresenius Kabi Chips Away at Neulasta Market in Germany

May 28th 2020

By Tony Hagen

Fresenius Kabi has tapped pharmaceuticals distribution company medac to amplify sales of its pegfilgrastim biosimilar in Germany.